FDA OKs drug to treat bleeding disorder

Apr 30, 2007

The U.S. Food and Drug Administration has approved Humate-P for the treatment of a specific bleeding disorder called von Willebrand disease.

Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) was approved for prevention of excessive bleeding during and after surgery in certain patients with mild to severe von Willebrand disease, or vWD. The disease is the most common inherited bleeding disorder, affecting about 1 percent of the U.S. population.

Humate-P is the second biological product to be approved for the management of surgery and invasive procedures in patients with vWD in whom the medication desmopressin might not work. The first biological product, Aphanate, was approved by FDA in February. However, FDA officials said Humate-P is the first product specifically for patients with severe vWD who are undergoing major surgery.

Humate-P is manufactured by CSL Behring GmbH, located in Marburg, Germany.

Copyright 2007 by United Press International

Explore further: Succesful results in developing oral vaccine against diarrhea

add to favorites email to friend print save as pdf

Related Stories

New fish test for virus is nonlethal

Mar 19, 2013

(Phys.org) —Cornell researchers have successfully identified the presence of a deadly virus—the viral hemorrhagic septicemia virus (VHSV)—by using techniques that are not lethal to fish.

New measures could improve quality of care at stroke centers

Jan 13, 2011

The American Heart Association/American Stroke Association has proposed metrics that healthcare professionals can use to monitor the diagnosis and treatment of patients at stroke centers to help improve the quality of care ...

Recommended for you

New sleeping pill poised to hit US markets

15 hours ago

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Global recommendations on child medicine

15 hours ago

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

FDA has safety concerns on Merck insomnia drug

May 20, 2013

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

User comments : 0

More news stories

Theorists weigh in on where to hunt dark matter

(Phys.org) —Now that it looks like the hunt for the Higgs boson is over, particles of dark matter are at the top of the physics "Most Wanted" list. Dozens of experiments have been searching for them, but ...

DNA damage: The dark side of respiration

(Phys.org) —Adventitious changes in cellular DNA can endanger the whole organism, as they may lead to life-threatening illnesses like cancer. Researchers at LMU now report how byproducts of respiration cause mispairing ...